Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

ClinicalTrials.gov ID: NCT01529827

Public ClinicalTrials.gov record NCT01529827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation

Study identification

NCT ID: NCT01529827
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Roswell Park Cancer Institute; Other
Enrollment: 94 participants

Conditions and interventions

Conditions

Interventions

allogeneic hematopoietic stem cell transplantation Procedure
fludarabine phosphate Drug
laboratory biomarker analysis Other
melphalan Drug
methotrexate Drug
mycophenolate mofetil Drug
peripheral blood stem cell transplantation Procedure
tacrolimus Drug
total-body irradiation Radiation

Procedure · Drug · Other + 1 more

Eligibility (public fields only)

Age range: 3 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 27, 2012
Primary completion: May 27, 2015
Completion: Aug 28, 2019
Last update posted: Sep 23, 2019

2012 – 2019

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Roswell Park Cancer Institute	Buffalo	New York	14263	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01529827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 23, 2019 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01529827 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →